Literature DB >> 1541968

Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids.

H S Markus1, N Hopkinson.   

Abstract

It has been reported that migraine is common in systemic lupus erythematous (SLE) and an association with phospholipid antibodies has been suggested. The incidence of migraine and non-migrainous headache was prospectively studied in 90 patients with SLE and 90 age- and sex-matched controls. A history of migraine was commoner in SLE patients than in controls [31(34%) vs 15(16%); P less than 0.05], and the mean age of onset was higher in the SLE group (26.8 vs 17.2 years). Within the SLE group an association was found between migraine and SLE disease activity. Non-migrainous headaches were also more common (non-significant) in the SLE group, and there was a close temporal relationship between onset of both headache and SLE in many patients. Both migraine and non-migrainous headaches in SLE patients often responded to specific SLE treatment. No association was found between migraine or other headaches and antibodies to phospholipids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541968     DOI: 10.1007/bf00839210

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

Review 1.  The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies.

Authors:  S R Levine; K M Welch
Journal:  Arch Neurol       Date:  1987-08

2.  Headache in patients with systemic lupus erythematosus: clinical and telethermographic findings.

Authors:  G P Anzola; G Dalla Volta; G Balestrieri
Journal:  Arch Neurol       Date:  1988-10

3.  IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.

Authors:  M E Cronin; R M Biswas; C Van der Straeton; T A Fleisher; J H Klippel
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

4.  Towards a definition of migraine headache.

Authors:  J N Blau
Journal:  Lancet       Date:  1984-02-25       Impact factor: 79.321

5.  Cerebrovascular ischemia associated with lupus anticoagulant.

Authors:  S R Levine; K M Welch
Journal:  Stroke       Date:  1987 Jan-Feb       Impact factor: 7.914

6.  Risk factors for thrombosis in lupus patients.

Authors:  P Hasselaar; R H Derksen; L Blokzijl; M Hessing; H K Nieuwenhuis; B N Bouma; P G De Groot
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

7.  Migrainous phenomena in systemic lupus erythematosus.

Authors:  K D Brandt; S Lessell
Journal:  Arthritis Rheum       Date:  1978 Jan-Feb

8.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

9.  A prospective study of chronic or recurrent headache in systemic lupus erythematosus.

Authors:  J Vázquez-Cruz; H Traboulssi; A Rodriquez-De la Serna; C Geli; C Roig; C Diaz
Journal:  Headache       Date:  1990-03       Impact factor: 5.887

10.  Migraine and anti-phospholipid antibodies.

Authors:  A Shuaib; L Barklay; M A Lee; O Suchowersky
Journal:  Headache       Date:  1989-01       Impact factor: 5.887

View more
  8 in total

1.  Prevalence and classification of headache in patients with systemic lupus erythematosus.

Authors:  Bruno Lessa; Alex Santana; Isabella Lima; José Martônio Almeida; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

2.  [Neurological manifestations in connective tissue disease].

Authors:  L Harms; F Hiepe
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

3.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

4.  [Immunological abnormalities in migraine and cluster headache-epiphenomenon or pathogenetic factors?].

Authors:  C Heesen; F Engler
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

Review 5.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

6.  Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.

Authors:  Tomasz Hawro; Andrzej Bogucki; Maria Krupińska-Kun; Marcus Maurer; Anna Woźniacka
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 7.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

8.  Constraints on Biological Mechanism from Disease Comorbidity Using Electronic Medical Records and Database of Genetic Variants.

Authors:  Steven C Bagley; Marina Sirota; Richard Chen; Atul J Butte; Russ B Altman
Journal:  PLoS Comput Biol       Date:  2016-04-26       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.